# Hepatoprotectants

# ≈hepatics

- 1. Inhibitors of nuclear transcription factor B (NF- $\kappa$ B)
- 2. Antifibrotics
- 3. Antioxidants
- 4. Compounds which interfere with apoptosis
- •most of compounds have multiple mechanisms of action

Nuclear transcription factor B (NF- $\kappa$ B)

= a protein activating the immunity response of Kupfer cells of liver to harmful stimuli

•permanent or excessive activation leads to unwanted changes of liver tissue (cirrhosis, fibrosis)

-under different circumstances, activation of NF- $\kappa$ B can lead also to liver regeneration

Activation of nuclear transcription factor B (NF- $\kappa$ B) by tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and interleukin 1 (IL-1) TNF-a **TNF-***α* receptor **IL-1** receptor MYD88 TRAF6 TRADD TRAF2 RIP IRAK Cytoplasm IKKK IKK IKK е IκB IKB NF-KB Ub (Ub) Nuclear localization signal. Ub Degradation of IKB NF-KB NF-KB translocation to nucleus Transcription of genes Nucleus NF-KB DNA DNA


NF- $\kappa$ B is in the cytoplasma in its inactive form linked with protein I $\kappa$ B (inhibitor  $\kappa$ B); this interaction disables transfer of NF- $\kappa$ B into the cell nucleus. NF- $\kappa$ B is activated if TNF- $\alpha$  or IL-1 are bound to their receptors, that leads to activation of intracellular signals and adaptor proteins, such as MyD88 (gene of primary myeloid differentiation response 88), IRAK (IL-1R-asociated kinase) and TRAF-6 (TNF-asociated factor 6) for receptor IL-1 and TRADD (TNF-asocioated protein of death domain), RIP (receptor-interacting protein) and TRAF2 (TNF-asociated factor 2) for receptor TNF- $\alpha$ . These changes enable activation of IKKK (kinase of I $\kappa$ B kinase), which phosphorylates a activates IKK (I $\kappa$ B kinase), consisted from regulation subunit (IKK- $\gamma$ ) and two kinase subunits (IKK- $\alpha$ , IKK- $\beta$ ), that are responsible for phosphorylation of I $\kappa$ B. Then I $\kappa$ B is degraded by nuclear localisation signal and free NF- $\kappa$ B reaches the nucleus where it is bound to  $\kappa$ B enhancing elements of target gene and induce their transcription.

#### Silymarin

a mixture of flavanolignans gained by extraction of seeds of milk thistle(*Silybum marianum*; first referred by Pliny the Elder (= *Gaius Plinius Secundus* (23 AD – August 25, 79 AD) in 77 AD
 content in seeds 1.5 – 3.5 %

most of hepatoprotective activity is attributed to silvation (A+B) = silibinin; it represents 60 – 70
% of silvation

•in silvbin, hepatoprotective activity in liver damage by death cap (mushroom) (Amanita phalloides), ethanol, paracetamol, CCl, etc. was demonstrated.




Effects of silymarin and their mechanisms

•inhibition of activation of NF-κB was demonstrated on hepatoma and lymphoma cells; probably main mechanism of action

•antioxidation effect: enhances superoxide dismutase activity in lymphocytes and erythrocytes, inhibits lipoperoxidation

•increses glutathione level


•anticancerogenic effect in prostate carcinoma



PhEur: Silybi mariani extractum siccum rafinatum et normatum
silikristin + silidianin 20 – 45 %
silibinin A + B 40 – 65 %
isosilibinin A + B 10 – 20 %

### isosilybin A+B (= isosilibinin A+B)


•preparations Flavobion<sup>®</sup>, Lagosa<sup>®</sup>, Legalon<sup>®</sup>, Silygal<sup>®</sup>, Silymarin AL 50<sup>®</sup>



3,5,4'-*trans*-trihydroxystilbene


*Arachis* (peanut), *Vitis vinifera* (grapevine)
effects: antioxidant, anti-inflammatory, cancer prevention
prevention of fibrose development
protection before paracetamol toxicity and fibrosis caused by tetrachloromethane was demonstrated *in vitro*methylation of -OH does not decrease protective effects *in vivo*mechanism of action: inhibition of NF-κB activation

Curcuminoids •*Curcuma longa, Zingiberaceae* 



$R^1 = R^2 = -OCH_3$	curcumin
$R^{1}$ =-H $R^{2}$ =-CH <sub>3</sub>	demethoxycurkumin
R <sup>1</sup> =R <sup>2</sup> =-H	bisdemethoxycurcumin (syn. curcumin III)

•mechanisms of action : inhibition of NF- $\kappa$ B, TNF- $\alpha$  and IL-1 $\beta$ •strong antioxidant activity, scavengers of many ROS •lower cell membrane peroxidation •curcumin is also the approved food additive (E 100, C.I. 75300)



3-(2,3-dihydroxyphenyl)prop-2-enoic acid caffeic acid

•protection against damage by CCl<sub>4</sub>


•mechanisms of action:

1. inhibition of lipoxygenase 5 (which produces leucotriens damaging the liver)

2. inhibition NF- $\kappa$ B activation

3. free radicals scavenging


Pyrrolidine-2-carbodithioic acid




 •syn. pyrrolidine-2-dithiocarboxylic acid, "pyrrolidine dithiocarbamate", "prolinedithiocarbamate", PDTC, dithioproline
 •known at least since 1958 (Zuman, Zahradník)
 •mechanisms of action:

 1.antioxidant by complexation of metal cations which catalyse generation of free radicals
 2. inhibits activation of NF-κB

#### Thalidomide and its analogues



- 2-(2,6-dioxopiperidine-3-yl)-1*H*-isoindole-1,3(2*H*)-dion α -(N-phtalimido)glutarimide **thalidomide**
- •originally hypnotic
- •strong teratogene (Contergan<sup>®</sup>)
- •abandoned in 1970<sup>th</sup>, now tested for cancer therapy
- •anti-inflammatory, antifibrotic and anticirrhotic activity
- •účinný inhibitor NF- $\kappa B$




3-(3,4-dimethoxyphenyl)-3-(1,3-dioxo-1,3-dihydro-2*H* -isoindol-2-yl)propanamide 3-(phtalimido)-3-(3,4-dimethoxyphenyl)propanamide **PDP** 

## 2. Antifibrotics

•angiotensin II (AT-II) a ACE play probably important roles in formation of liver firbrose

•transforming growth factor  $\beta$  (TGF- $\beta$ ) plays a dominat role in fibrose initiation; it can be supported by AT-II


•angiotensin receptor 1 antagonists lowers the portal pressure in hepatic cirrhosis
•hypothesis: inhibition of AT-II leads to NF-κB inactivation




(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid captopril

(normally used as an anti-hypertensive agent)

3. Antioxidants





inhibition of apoptosis of hepatocytes which had been induced by actinomycine D and TNF-α was demonstrated
mechanism of action: activation of the insulin receptor by binding to thyrosinkinase domain
used and authorised for long time as a drug for diabetic polyneuropathy (Thioktacid<sup>®</sup>, Thiogamma<sup>®</sup>)

## 4. Compounds which interfere with apoptosis $NH_2$ N Н Н ́″́ОН Η Ο HO $CH_3$ $NH_2$

### S-adenosylmethionine

SAME, SAM, AdoMet

•endogenous compound, a donor of methyl

•synthesized from Met and ATP by the reaction catalyzed by methionine


adenosyltransferase (MAT)

•regulates liver growth

•anti-apoptic in normal cells, induces apoptosis in cancer cells; a mechanism of action related to proteins Bcl-x was proposed (Bcl-x belong to BCI-2c family, members of this family are central regulators of apoptosis); posttranslation splicing of Bcl-x protein can lead to Bcl-x<sub>L</sub>, that is anti-apoptic, or to Bcl-x<sub>s</sub> which is proapoptic; SAME and methionyladenosin (MTA) induced selectively Bcl-x<sub>s</sub> in HepG2 cancer cells; the alternative splicing is modulated by proteinphosphatase 1 (PP1) and its inhibitors block the ability of SAME and MTA induce Bcl-x<sub>s</sub>

•SAME and MTA increased the amount of mRNA for the catalytic subunit PP1 in HepG2 cells, but not in normal hepatocytes

•SAME is freely available in food supplements in the USA



#### methylthioadenosine (MTA)

5'-deoxy-5'-methylsulfanyladenosine

•a side product of SAME metabolism gained in polyamines synthesis

The hepatal metabolism of S-adenosylmethionine (SAME)

